Some good news (and incredibly fast work) on one of the mutations scientists are worried about: N501Y.
In these lab experiments serum from recovered #covid19 patients was just as good at neutralizing virus with the mutation as without it.
This does not say anything about whether the mutation could make the virus more transmissible but it suggest the mutation alone at least does not mean the virus can widely infect people again.
Of course, both UK and SA variant have several additional mutations...
I will let other people figure out how to cite a tweet in a scientific publication ;)
And a caveat that I did not think I would ever write:
This is not a peer-reviewed scientific paper but a tweet, so uhmmm, yeah obviously good to wait for a bit more data and so on...
Seeing a lot of people say this shows vaccines work against the UK variant. No. This is serum from naturally infected patients (not vaccinated) and the virus is not the UK variant, it just carries one of its mutations!
It’s still good news. And I’ll happily take that.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Kai Kupferschmidt

Kai Kupferschmidt Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @kakape

24 Dec
What do we know about the new #SARSCoV2 variants? How worried should we be? What does it mean?
I promised to summarize the main points from my reporting over the last few days.
So here is my latest story and a thread (and then it’s Christmas)
sciencemag.org/news/2020/12/u…
First: I’ve said “We don’t know yet” a lot over the last few days and we still don’t know most of what we want to know about these variants. Getting good answers takes times. Science takes time. But we are learning a lot fast and we know a lot more today than three days ago.
The UK variant:
I explained how B.1.1.7 caught scientists’ attention in my first story on this and why they were worried (sciencemag.org/news/2020/12/m…).
That worry has only increased. There is now more data available and it points to this variant really being more transmissible.
Read 20 tweets
21 Dec
It’s becoming clearer that one main hypothesis that scientists are looking at with B.1.1.7 is whether its advantage could be that it is better at infecting children. There are a TON of caveats, but this is one possibility that is being explored.
The idea is very simple: #SARSCoV2 appears to be a bit worse at infecting children than adults. If the mutations in B.1.1.7 allow this variant to bind more tightly to the ACE2 receptor on human cells that could essentially make it as good at infecting children as adults.
Like I said a TON of caveats. Maybe most importantly: the UK had a lockdown while schools were kept open, so you would expect the epidemic to shift more to children anyway and that of course can make it look like there is something going on with this variant in children.
Read 4 tweets
20 Dec
There’s a lot of concern and confusion right now about the new #sarscov2 variant identified in UK. I’ve spent today and yesterday talking to a dozen people working on this. My story is here: sciencemag.org/news/2020/12/m…
Thread to come (may be long and slow)
There are a ton of things to explain, dozens of questions to discuss and I won’t be able to cover more than a tiny part here now. So three general things up front:
1. Expect more threads and stories on this from me
2. A lot of scientists are working on this. You can follow @firefoxx66, @arambaut, @K_G_Andersen, @GuptaR_lab, @pathogenomenick, @EvolveDotZoo, @jbloom_lab, @Tuliodna for starters.
Read 15 tweets
19 Dec
“We urge governments throughout Europe to agree on clearly formulated common goals, coordinate their efforts, develop regionally adapted strategies to reach the goals, and thereby work resolutely towards low case numbers”, @CiesekSandra, @ViolaPriesemann and others in @TheLancet
The lack of a European strategy is something scientists and public health experts have pointed out again and again and it’s good to see it clearly formulated by a group of prominent researchers thelancet.com/journals/lance…
The authors also give a good, succinct summary of arguments for going for low #covid19 case numbers:
1. saving lives
2. saving the economy
3. control is more effective
4. makes TTI feasible
5. natural acquired herd immunity is not an option
6. no need for rapid policy changes
Read 4 tweets
19 Dec
Meine Kollegen vom @pandemiapodcast und ich haben viele Fragen bekommen in den vergangenen Wochen zu den neuen Impstoffen, zu ihrer schnellen Entwicklung, ihrer Sicherheit, zu Impfbereitschaft und Impfpflicht. Wir wollten das natürlich aufnehmen.
@pandemiapodcast Die neue Folge ist darum ein etwas wilder Ritt querfeldein und wir binden zusammen, worüber wir in den ersten Folgen der zweiten Staffel gesprochen haben: Impfstoffe, Pocken, Masern und eben #SARSCoV2. Die Folge gibt es hier: viertausendhertz.de/pan16/
Als Nächstes dann Gelbfieber!
@pandemiapodcast Vielen lieben Dank an @florian_krammer, @CorneliaBetsch, @Karl_Lauterbach, @NatalieGrams und Sidney Chalhoub, die sich alle viel Zeit genommen haben, um mit uns für die Folge zu sprechen.
Read 4 tweets
18 Dec
Global vaccine news: COVAX says deals are in place to access nearly 2 billion doses of #covid19 vaccine. "For the vast majority of these deals, COVAX has guaranteed access to a portion of the first wave of production, followed by volume scales as further supply becomes available”
The new deals include:
- an advance purchase agreement with AstraZeneca for 170 million doses of the AstraZeneca/Oxford candidate
- a memorandum of understanding (MoU) with Johnson & Johnson for 500 million doses of the Janssen candidate (investigated as single dose vaccine)
That’s on top of:
- agreement with Serum Institute of India for 200 million doses (plus option for 900 million more doses) of either AZ or Novavax vaccine
- statement of intent for 200 million doses of Sanofi/GSK vaccine candidate
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!